TIDMDNL

RNS Number : 0096P

Diurnal Group PLC

14 October 2021

14 October 2021

Diurnal Group plc

("Diurnal" or the "Company")

Appointment of Joint Corporate Broker

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the appointment of Stifel Nicolaus Europe Limited as Joint Corporate Broker alongside Panmure Gordon, the existing Corporate Broker and Nominated Adviser, with immediate effect.

 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                    +44 (0)20 3727 
 Diurnal Group plc                                   1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser     +44 (0)20 7886 
  and Joint Corporate Broker)                        2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: Rupert Dearden 
 
 Stifel Nicolaus Europe Limited (Joint Corporate    +44 (0) 20 7710 
  Broker)                                            7600 
 Healthcare Investment Banking: Nicholas Moore, 
  Samira Essebiyea 
 Corporate Broking: Nick Adams 
 
                                                    +44 (0)20 3727 
 FTI Consulting (Media and Investor Relations)       1000 
 Simon Conway 
 Victoria Foster Mitchell 
 Alex Davis

Notes to Editors

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPFLFIDIFLVLIL

(END) Dow Jones Newswires

October 14, 2021 02:01 ET (06:01 GMT)

Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Diurnal.
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Diurnal.